Company profile: Valitor Bio
1.1 - Company Overview
Company description
- Provider of novel methods to modify therapeutic proteins for control over pharmacological properties, including VLTR-559, a long-acting treatment for wet age-related macular degeneration designed to extend a single dose to six months or more; VLTR-557, a long-acting anti-VEGF biologic with potential six-month efficacy from one intravitreal injection; and Multivalent Polymer (MVP) Technology to enhance potency, durability, and safety.
Products and services
- Multivalent Polymer (MVP) Technology: A proprietary platform using multivalent biopolymers to independently control multiple drug attributes, enhancing potency, durability, and safety across therapeutic proteins
- VLTR-559: A long-acting treatment for wet age-related macular degeneration that extends a single dose's duration to six months or more
- VLTR-557: A long-acting anti-VEGF biologic under development for durable wet AMD treatment, targeting six-month efficacy from a single intravitreal injection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Valitor Bio
OncoMed
HQ: United States
Website
- Description: Provider of biotechnology therapeutics developing monoclonal antibodies that target pathways critical to tumor-initiating (cancer stem) cells to improve cancer treatment. Pipeline includes etigilimab with nivolumab for advanced solid tumors, navicixizumab for platinum-resistant ovarian cancer (with OncXerna), setrusumab for OI, alvelestat for AATD-LD, acumapimod for AECOPD, and leflutrozole (with ReproNovo).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoMed company profile →
Aptevo Therapeutics
HQ: United States
Website
- Description: Provider of bispecific immunotherapies and platform technologies for cancer treatment, focused on oncology and hematology. Portfolio includes ADAPTIR and ADAPTIR-FLEX platforms, plus candidates APVO436 (CD3xCD123, Phase 2 AML), APVO603 (4-1BB/OX40), APVO442 (PSMA/CD3 for prostate cancer), and APVO711 (PD-L1/CD40).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aptevo Therapeutics company profile →
Broncus Medical
HQ: United States
Website
- Description: Provider of minimally invasive medical devices for emphysema and other lung diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Broncus Medical company profile →
GigaGen
HQ: United States
Website
- Description: Provider of recombinant biotherapeutic discovery and development, advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world's first recombinant polyclonal hyperimmune gammaglobulin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GigaGen company profile →
MDxHealth
HQ: United States
Website
- Description: Provider of molecular diagnostics and epigenetic tests for cancer assessment and personalized treatment, including Select mdx (urine test to identify men at risk for aggressive prostate cancer before an initial biopsy), Confirm mdx (tissue test for risk of undetected clinically significant prostate cancer after a negative biopsy), Genomic Prostate Score (predicts disease aggressiveness), and Resolve mdx (PCR UTI test with personalized antibiotic options).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDxHealth company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Valitor Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Valitor Bio
2.2 - Growth funds investing in similar companies to Valitor Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Valitor Bio
4.2 - Public trading comparable groups for Valitor Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →